Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Amgen Inc. stock: Pipeline pivot eyes $37-38B sales amid biosimilar risks
Amgen Inc. is strategically pivoting its pipeline to achieve $37-38.4 billion in sales by 2026, driven by next-generation drugs like the obesity candidate MariTide. This move is crucial for counteracting biosimilar erosion on its legacy products and positions Amgen as a resilient biotech play with strong dividend potential for global investors. The company aims to balance mature cash cows with innovative treatments in key areas like obesity and oncology, while maintaining robust financial health and attractive margins.